The purpose of this study was to identify biomarkers at presentation that are associated with a persistent central serous chorioretinopathy (CSC) episode.
Methods
The prospective study included 35 patients with an acute CSC episode. Potential clinical and imaging biomarkers were evaluated at baseline and 3 months from the episode onset. As biomarkers age, sex, steroid use, episode recurrence, central retinal thickness (CRT), macular volume (MV), choroidal thickness (CT), pigment epithelial detachment (PED) height, and width, number of retinal hyperreflective foci (HF), leakage pattern, and area of retinal pigment epithelial (RPE) alterations were investigated.
Results
At 3 months from the CSC episode onset, spontaneous resolution occurred in 19 patients, while 16 patients had a persistent CSC episode. The group of patients with a persistent episode was statistically significantly associated with female sex (p = 0.032), older age (p = 0.015), wider PED (p = 0.005), and higher number of HF (p = 0.02). Moreover, this group of patients had a significant association with thinner choroid and diffuse RPE alterations as a pair (p = 0.008).
Conclusions
Older and female CSC patients with wider PED, increased number of HF, thinner choroid, and diffuse RPE alterations at presentation are inclined to episode persistence and could benefit from earlier treatment.
DaruichAMatetADiraniA, et al.Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retinal Eye Res2015; 48: 82–118.
2.
DaruichAMatetAMarchionnoL, et al.ACUTE CENTRAL SEROUS CHORIORETINOPATHY: factors influencing episode duration. Retina (Philadelphia, Pa)2017; 37(10): 1905–1915.
3.
BaranNVGürlüVPEsginH. Long-term macular function in eyes with central serous chorioretinopathy. Clin Exp Ophthalmol2005; 33(4): 369–372.
4.
GawęckiMJaszczuk-MaciejewskaAJurska-JaśkoA,et al.Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy. BMC Ophthalmol2019; 19(1): 160.
5.
SinghSRMatetAvan DijkEHC, et al.Discrepancy in current central serous chorioretinopathy classification. Br J Ophthalmol2019; 103(6): 737–42.
YuJXuGChangQ, et al.Risk factors for persistent or recurrent central serous chorioretinopathy. J Ophthalmol2019; 2019: 5970659.
8.
RobertsonDMIlstrupD. Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol1983; 95(4): 457–466.
9.
van DijkEHCFauserSBreukinkMB, et al.Half-Dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial. Ophthalmology2018; 125(10): 1547–1555.
10.
BousquetEZhaoMDaruichA,et al.Mineralocorticoid antagonists in the treatment of central serous chorioetinopathy: review of the pre-clinical and clinical evidence. Exp Eye Res2019; 187: 107754.
NkrumahGPaez-EscamillaMSinghSR, et al.Biomarkers for central serous chorioretinopathy. Therapeutic Adv Ophthalmol2020; 12: 2515841420950846.
13.
YangLJonasJBWeiW. Optical coherence tomography-assisted enhanced depth imaging of central serous chorioretinopathy. Invest Ophthalmol Visual Sci2013; 54(7): 4659–4665.
14.
AmbiyaVYogiRLiA, et al.Subfoveal choroidal thickness as a predictor of central serous chorioretinopathy. Eye (London, England)2016; 30(12): 1623–1629.
15.
LeeHLeeJChungH,et al.Baseline spectral domain optical coherence tomographic hyperreflective foci as a predictor of visual outcome and recurrence for central serous chorioretinopathy. Retina (Philadelphia, Pa)2016; 36(7): 1372–1380.
16.
ChenSNHwangJFTsengLF,et al.Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage. Ophthalmology2008; 115(12): 2229–2234.
17.
BorrelliEZuccaroBZucchiattiI, et al.Optical coherence tomography parameters as predictors of treatment response to eplerenone in central serous chorioretinopathy. J Clin Med2019; 8(9): 1271.
18.
PokharelAShresthaGSShresthaJB. Macular thickness and macular volume measurements using spectral domain optical coherence tomography in normal Nepalese eyes. Clin Ophthalmol (Auckland, NZ)2016; 10: 511–519.
19.
MohabatiDSchellevisRLvan DijkEHC, et al.Genetic risk factors in severe, nonsevere and acute phenotypes of central serous chorioretinopathy. Retina2020; 40(9): 1734–1741.
20.
MrejenSBalaratnasingamCKadenTR, et al.Long-term visual outcomes and causes of vision loss in chronic central serous chorioretinopathy. Ophthalmology2019; 126(4): 576–588.
21.
Early treatment diabetic retinopathy study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology1991; 98(5 Suppl): 741–756.
22.
BaeSJinKKimH,et al.Clinical parameters related to metamorphopsia outcome in patients with resolved central serous chorioretinopathy using M-CHARTS: retrospective cohort study. BMC Ophthalmol2015; 15: 180.
23.
MaaranenTHTuppurainenKTMäntyjärviMI. Color vision defects after central serous chorioretinopathy. Retina (Philadelphia, Pa)2000; 20(6): 633–637.
24.
ChappelowAVMarmorMF. Multifocal electroretinogram abnormalities persist following resolution of central serous chorioretinopathy. Arch Ophthalmol (Chicago, Ill : 1960)2000; 118(9): 1211–1215.
25.
SpaideRFCampeasLHaasA, et al.Central serous chorioretinopathy in younger and older adults. Ophthalmology1996; 103(12): 2070–2079. discussion 9–80.
26.
ChenMRajapakseDFraczekM,et al.Retinal pigment epithelial cell multinucleation in the aging eye - a mechanism to repair damage and maintain homoeostasis. Aging Cell2016; 15(3): 436–445.
27.
GaoHHollyfieldJG. Aging of the human retina. Differential loss of neurons and retinal pigment epithelial cells. Invest Ophthalmol Visual Sci1992; 33(1): 1–17.
28.
RashidABhatiaSKMazzitelloKI, et al.RPE Cell and sheet properties in normal and diseased eyes. Adv Exp Med Biol2016; 854: 757–763.
29.
GourasPIvertLNeuringerM,et al.Mitochondrial elongation in the macular RPE of aging monkeys, evidence of metabolic stress. Graefe’s Arch Clin Exp Ophthalmol2016; 254(6): 1221–1227.
30.
SparrowJRHicksDHamelCP. The retinal pigment epithelium in health and disease. Curr Mol Med2010; 10(9): 802–823.
31.
NicholsonBNobleJForooghianF,et al.Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol2013; 58(2): 103–126.
32.
LiMQuJLiangZ, et al.Risk factors of persistent subretinal fluid after half-dose photodynamic therapy for treatment-naïve central serous chorioretinopathy. Graefe’s Arch Clin Exp Ophthalmol2022; 260(7): 2175–2182.
33.
KiralyPSmrekarJJaki MekjavićP. Morphological parameters predicting subthreshold micropulse laser effectiveness in central serous chorioretinopathy. Lasers Med Sci2022; 37(8): 3129–3136.
34.
RizzoloLJPengSLuoY,et al.Integration of tight junctions and claudins with the barrier functions of the retinal pigment epithelium. Prog Retinal Eye Res2011; 30(5): 296–323.
35.
LoteryASivaprasadSO’ConnellA, et al.VICI trial investigators. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet2020 Jan 25; 395(10220): 294–303.
36.
HanumunthaduDMatetARasheedMA,et al.Evaluation of choroidal hyperreflective dots in acute and chronic central serous chorioretinopathy. Indian J Ophthalmol2019; 67(11): 1850–1854.
37.
YalcinbayirOGeliskenOAkova-BudakB,et al.Correlation of spectral domain optical coherence tomography findings and visual acuity in central serous chorioretinopathy. Retina (Philadelphia, Pa)2014; 34(4): 705–712.
